|Bid||655.55 x 1100|
|Ask||736.68 x 800|
|Day's Range||720.31 - 746.02|
|52 Week Range||472.84 - 756.52|
|Beta (5Y Monthly)||0.81|
|PE Ratio (TTM)||5.42|
|Earnings Date||Oct 27, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||755.00|
Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.
Today, we will review the second quarter 2021 financial results and provide an update on key business trends for Bio-Rad. With me on the phone today are Norman Schwartz, our Chief Executive Officer; Ilan Daskal, Executive Vice President and Chief Financial Officer; Andy Last, Executive Vice President and Chief Operating Officer; Annette Tumolo, President of the Life Science Group; and Dara Wright, President of the Clinical Diagnostics Group.
Bio-Rad (BIO) delivered earnings and revenue surprises of 86.32% and 17.29%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?